Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
NCT05557877
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 45 years
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- Mayo Clinic
- Last updated on ClinicalTrials.gov
- October 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Mayo Clinic in Florida · Jacksonville, FL
Indiana · 1
- Indiana University Simon Comprehensive Cancer Center · Indianapolis, IN
Minnesota · 1
- Mayo Clinic in Rochester · Rochester, MN
North Carolina · 1
- University of North Carolina · Chapel Hill, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.